BELLUS Health reports results for first half of f...(research and development expenses incurr...),Health

General and administrative expenses totaled $1,209,000 for the current quarter ($4,357,000 for the six-month period), compared to $2,373,000 for the same quarter the previous year ($5,949,000 for the six-month period). Expenses for the current three-month period are presented net of an amount of $1,245,000 in relation to amortization of the deferred gain on sale of property ($1,580,000 for the six-month period) compared to $334,000 for the corresponding period the previous year ($669,000 for the six-month period). Refer to Liquidity and Capital Resources section for details.

Marketing and selling expenses amounted to $560,000 for the current quarter ($2,438,000 for the six-month period) compared to $2,035,000 for the same quarter and six-month period of the previous year and represent expenses incurred in relation to the commercialization of the Company's natural health brand, VIVIMIND(TM).

Stock-based compensation amounted to $724,000 for the current quarter ($1,176,000 for the six-month period), compared to $824,000 for the corresponding quarter the previous year ($1,859,000 for the six-month period). This expense relates to stock options and stock-based incentives, whereby compensation cost in relation to stock options is measured at fair value at the date of grant and is expensed over the award's vesting period. The decrease in the six-month period is mainly due to adjustments in relation to forfeitures of stock options, which occurred as a result of reductions in the workforce.

Net credit for vacant space amounted to $2,196,000 and is in relation to the vacancy of a portion of the Company's premises following the reduction in the Company's research activities and associated workforce. Refer to Liquidity and Capital resources section for details.

Interest income amounted to $30,000 for the current quarter ($43,000 for the six-month period) co
'/>"/>